• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AdventHealth and Sema4 Launch a Data-driven Precision Medicine Program to Optimize Patient Care and Outcomes

    5/25/21 7:00:00 AM ET
    $CMLF
    Business Services
    Finance
    Get the next $CMLF alert in real time by email

    Expanding their investment in precision medicine, AdventHealth is leveraging Sema4's health intelligence platform to enable a range of clinical and research initiatives

    AdventHealth and Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced a wide-ranging collaboration that builds upon the current AdventHealth Genomics and Personalized Health Program to provide new research insights and to prevent, detect and treat disease in their patients.

    Initially, AdventHealth and Sema4 will focus on accelerating research in AdventHealth's Orlando-area network, which includes more than 20 hospitals and emergency departments, and accounts for more than two million patient visits annually. Nationally, the company has 50 hospitals and hundreds of care sites across almost a dozen states. The collaboration will offer genomic solutions to patients across a number of services and specialties.

    "AdventHealth views genomics and personalized medicine as critical to the future of wellness and health care, and we are delighted to collaborate with Sema4 on this important journey," said Dr. Steven R. Smith, chief scientific officer for AdventHealth. "This technology and collaboration will allow us to interpret vast amounts of clinical, genomic and other patient data to discover and provide lifesaving treatments to patients who previously would not have had those options."

    At the center of this precision medicine collaboration, AdventHealth and Sema4 will conduct data structuring and curation of the combined genomic and clinical data, which, along with Sema4 investigative tools, will allow clinicians and scientists to advance research and discovery. The collaboration will use Centrellis™, Sema4's secure, holistic cloud-based health intelligence platform, in this effort. Sema4 will apply artificial intelligence tools to structure and integrate the longitudinal patient data with the molecular testing data, developing a data set and disease network models that assist in predicting the development of disease and response to treatments.

    "AdventHealth is a premier health system with a longstanding commitment to wellness and personalizing health care for its patients, making it an ideal partner for Sema4," said Eric Schadt, PhD, founder and CEO of Sema4. "We are excited to use our sophisticated artificial intelligence tools to collaborate with AdventHealth scientists and clinicians to deliver improved health outcomes through data-driven insights."

    The collaboration is an important expansion of AdventHealth's wide ranging Genomics and Personalized Health Program, which already includes major investments in sequencing, genetic testing, genetic counseling and real-world precision medicine research. A leading element of that program is WholeMe, a statewide genomic population health project.

    About the AdventHealth Central Florida Division

    AdventHealth's Central Florida Division encompasses more than 20 hospitals and ERs, as well as a comprehensive outpatient care network, in the seven counties in and surrounding metro Orlando. The division's flagship campus — AdventHealth Orlando — boasts internationally recognized programs, and serves as a major tertiary referral hospital for much of the Southeast, the Caribbean and Latin America. Quality specialty care is provided through AdventHealth Institutes, which is nationally recognized in numerous specialties. AdventHealth also has an expansive research portfolio with more than 500 clinical trials in progress. The organization has a deep commitment to serving the community and has a local financial impact of more than $1 billion annually. AdventHealth and its employees are responsible for nearly 20 percent of Central Florida's economy. Learn more in our newsroom.

    About Sema4

    Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all. For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005284/en/

    Get the next $CMLF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMLF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CMLF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

      37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

      3/14/22 4:05:00 PM ET
      $CMLF
      $SMFR
      Business Services
      Finance
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

      Sema4 Holdings Corp ("Sema4") to debut on Nasdaq as a publicly traded company dedicated to transforming healthcare by applying artificial intelligence and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human healthBusiness combination expected to result in ~$500 million in cash proceeds to Sema4 to accelerate organic and inorganic growthCombined company to trade on Nasdaq under ticker "SMFR" STAMFORD, Conn., July 22, 2021 (GLOBE NEWSWIRE) -- Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the completion of its business combination with CM Life

      7/22/21 9:15:41 AM ET
      $TWST
      $MGTA
      $CMLF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Business Services
    • Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors

      Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of renowned executive Jason Ryan to its Board of Directors. Mr. Ryan will begin serving on Sema4's Board of Directors upon his official appointment after Sema4 closes its previously announced business combination with CM Life Sciences (NASDAQ:CMLF), a special purpose acquisition company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005228/en/Jason Ryan (Photo: Business Wire) Mr. Ryan most recently served as Chief Operating and Financial Officer of Magenta Therapeutics (NA

      7/7/21 7:00:00 AM ET
      $TWST
      $CMLF
      $MGTA
      $OMIC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Business Services
      Finance

    $CMLF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sherman Rachel E.

      4 - Sema4 Holdings Corp. (0001818331) (Issuer)

      10/19/21 7:31:01 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form 4 filed by Turner Nat

      4 - Sema4 Holdings Corp. (0001818331) (Issuer)

      10/19/21 7:29:25 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form 4 filed by Pellini Michael J

      4 - Sema4 Holdings Corp. (0001818331) (Issuer)

      10/19/21 7:27:37 PM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    SEC Filings

    See more
    • SEC Form 424B3 filed by CM Life Sciences, Inc.

      424B3 - Sema4 Holdings Corp. (0001818331) (Filer)

      10/14/21 9:58:15 PM ET
      $CMLF
      Business Services
      Finance
    • CM Life Sciences, Inc. filed SEC Form 8-K: Leadership Update

      8-K - Sema4 Holdings Corp. (0001818331) (Filer)

      10/14/21 5:23:09 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form S-8 filed by CM Life Sciences, Inc.

      S-8 - Sema4 Holdings Corp. (0001818331) (Filer)

      9/27/21 4:46:23 PM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by CM Life Sciences, Inc.

      SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

      10/13/21 2:31:34 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form SC 13D filed by CM Life Sciences, Inc.

      SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

      8/30/21 4:45:58 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form SC 13D filed by CM Life Sciences, Inc.

      SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

      8/2/21 4:59:57 PM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    Leadership Updates

    Live Leadership Updates

    See more
    • Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data Officer

      Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of Andrew Kasarskis, PhD, to the newly established role of Chief Data Officer (CDO). Dr. Kasarskis brings more than 20 years of leadership and broad experience in industry and academia that includes a strong focus on digital analytics and genomics and internationally recognized research in the life sciences. At Sema4, he will be responsible for establishing additional structures and processes to further optimize the company's health intelligence platform and orchestrating data use and data science to support research, development, and innov

      6/17/21 7:00:00 AM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    Financials

    Live finance-specific insights

    See more
    • Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

      37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

      3/14/22 4:05:00 PM ET
      $CMLF
      $SMFR
      Business Services
      Finance
      Retail: Computer Software & Peripheral Equipment
      Technology